17:25 , Sep 28, 2018 |  BC Week In Review  |  Clinical News

CHMP backs Luxturna, Lilly's migraine mAb, antibiotic Vabomere

EMA's CHMP on Sept. 21 recommended several therapies for approval, including gene therapy Luxturna voretigene neparvovec, migraine mAb Emgality galcanezumab and antibiotic Vabomere meropenem/vaborbactam. CHMP also confirmed its negative opinion for Exondys eteplirsen from Sarepta...
21:45 , Sep 21, 2018 |  BC Extra  |  Company News

CHMP backs Luxturna, Lilly's migraine mAb, antibiotic Vabomere

EMA's CHMP Friday recommended several therapies for approval, including gene therapy Luxturna voretigene neparvovec, migraine mAb Emgality galcanezumab and antibiotic Vabomere meropenem/vaborbactam. CHMP also confirmed its negative opinion for Exondys eteplirsen from Sarepta Therapeutics (NASDAQ:SRPT)...
16:48 , Mar 16, 2018 |  BC Week In Review  |  Financial News

Energy firm spins out biotech with $40M series A

Energy company TAE Technologies Inc. (Foothill Ranch, Calif.) spun out TAE Life Sciences (Foothill Ranch, Calif.) into a biotech subsidiary to develop a radiation therapy for cancer. The spinout raised $40 million in a series...
12:00 , Mar 12, 2018 |  BC Extra  |  Financial News

Energy firm spins out biotech with $40M series A

Energy company TAE Technologies Inc. (Foothill Ranch, Calif.) spun out TAE Life Sciences (Foothill Ranch, Calif.) into a biotech subsidiary to develop a radiation therapy for cancer. The spinout raised $40 million in a series...
01:09 , Feb 16, 2018 |  BC Innovations  |  Strategy

Pfizer’s chemistry machine

With the goal of creating a step-change in the optimization of small molecules in discovery research, Pfizer Inc. has built a continuous flow machine that rapidly tests thousands of chemical reactions using submilligram quantities of...
21:55 , Dec 1, 2017 |  BC Week In Review  |  Company News

Melinta acquires Medicines Co.'s infectious disease unit

Melinta Therapeutics Inc. (NASDAQ:MLNT) will acquire the infectious disease business unit of The Medicines Co. (NASDAQ:MDCO), including marketed drugs Vabomere meropenem/vaborbactam, Orbactiv oritavancin and Minocin IV minocycline. Medicines Co. will receive $270 million up front,...
00:16 , Nov 30, 2017 |  BC Extra  |  Company News

Melinta acquires Medicines Co.'s infectious disease unit

Melinta Therapeutics Inc. (NASDAQ:MLNT) will acquire the infectious disease business unit of The Medicines Co. (NASDAQ:MDCO), including marketed drugs Vabomere meropenem/vaborbactam, Orbactiv oritavancin and Minocin IV minocycline. Medicines Co. will receive $270 million up front,...
15:18 , Sep 1, 2017 |  BC Week In Review  |  Clinical News

FDA approves cUTI combo Vabomere from MDCO

FDA approved Vabomere meropenem/vaborbactam (Carbavance) from The Medicines Co. (NASDAQ:MDCO) to treat adults with complicated urinary tract infections (cUTI) including pyelonephritis caused by Escherichia coli , Klebsiella pneumoniae and Enterobacter cloacae species complex. The company...
21:06 , Aug 30, 2017 |  BC Extra  |  Company News

FDA approves cUTI combo from MDCO

After market close Tuesday, FDA said it approved Vabomere meropenem/vaborbactam from The Medicines Co. (NASDAQ:MDCO) to treat adults with complicated urinary tract infections (cUTI) including pyelonephritis caused by Escherichia coli , Klebsiella pneumoniae and Enterobacter...
02:14 , Feb 23, 2017 |  BC Week In Review  |  Clinical News

Carbavance regulatory update

FDA accepted and granted Priority Review to an NDA from The Medicines Co. for IV Carbavance meropenem/vaborbactam to treat complicated urinary tract infections (cUTIs). The company declined to disclose the PDUFA date, but said FDA...